A61L2300/402

SETTABLE SURGICAL IMPLANTS AND THEIR PACKAGING
20230191004 · 2023-06-22 ·

The present invention relates to settable compositions for use in surgery. The invention also provides related compositions, including surgical kits and packages, as well as methods of making and using the settable compositions.

SILK-HYALURONIC ACID BASED TISSUE FILERS AND METHODS OF USING THE SAME
20230190997 · 2023-06-22 ·

Hyaluronic acid and silk protein fragments based tissue fillers and methods of the same are provided herein.

Methods and compositions for treating post-operative pain comprising clonidine

The present invention is directed to an implantable drug depot useful for reducing, preventing or treating post-operative pain in a patient in need of such treatment, the implantable drug depot comprising a therapeutically effective amount of clonidine or pharmaceutically acceptable salt thereof and a polymer; wherein the depot is implantable at a site beneath the skin to reduce, prevent or treat post-operative pain, and the depot is capable of releasing (i) about 5% to about 45% of the clonidine or pharmaceutically acceptable salt thereof relative to a total amount of the clonidine or pharmaceutically acceptable salt thereof loaded in the drug depot over a first period of up to 48 hours and (ii) about 55% to about 95% of the clonidine or pharmaceutically acceptable salt thereof relative to a total amount of the clonidine or pharmaceutically acceptable salt thereof loaded in the drug depot over a subsequent period of at least 3 days.

Settable surgical implants and their packaging
09827349 · 2017-11-28 · ·

The present invention relates to settable compositions for use in surgery. The invention also provides related compositions, including surgical kits and packages, as well as methods of making and using the settable compositions.

PLASTER FOR USE IN THE CONTEXT OF AN INTRAMUSCULAR INJECTION, IN PARTICULAR A VACCINATION
20230173134 · 2023-06-08 ·

The invention relates to a plaster for use in the context of an intramuscular injection, particularly a vaccination, having a patient side and an outer side, comprising: an adhesive layer on the patient side for attaching the plaster to the skin of a patient, an absorbent wound-covering on the patient side in the region of an intended intramuscular injection site, the absorbent wound-covering having received a disinfectant, and an opening on the outer side in the area of the absorbent wound-covering of the patient side for the injection needle.

COMPOSITION COMPRISING HYALURONIC ACID AND MEPIVACAINE
20220362439 · 2022-11-17 ·

Compositions and methods for the surface appearance of the skin a subject are provided. An injectable composition comprising at least hyaluronic acid or a salt thereof; and an effective amount of at least mepivacaine or a salt thereof are provided. The hyaluronic acid optionally has an average molecular weight ranging from 50,000 to 10,000,000 Daltons, and may be crosslinked hyaluronic acids, non-crosslinked hyaluronic acids, or a combination, in some embodiments. The compositions and methods of the present invention are useful for treating and preventing the cutaneous signs of chronological aging and/or induced by external factors such as stress, air pollution, tobacco or prolonged exposure to ultraviolet (UV) exposure, impaired surface appearance of the skin, impaired viscoelastic or biomechanical properties of the skin, and/or the long-lasting filling of volume defects of the skin.

FILMOGENIC COMPOSITIONS FOR TOPICAL ANAESTHETIC BIOADHESIVES - TABS, FOR CONTROLLED RELEASE OF ACTIVE PRINCIPLES AND TOPICAL ANAESTHETIC BIOADHESIVES

Filmogenic compositions are described for topical anaesthetic bioadhesives (TABs) comprising a) a xanthan biopolymer matrix selected from Xanthomonas species and pathovars, including Xanthomonas campestris pathovars campestris and maninhotis, and Xanthomonas arboricola pathovar pruni, a producer of pruni xanthan, wherein the matrix is made of pure or combined xanthan varieties in any proportion, said matrix comprising between 1% and 95% by weight of the total weight of the composition, and additives or excipients; b) at least one anaesthetic, in a proportion of 0.1% to 50% by weight of the total weight of the composition. The topical anaesthetic bioadhesives (TABs) are also described, and they may be applied to the gingival mucosa and/or alveolar mucosa on the buccal (1) or lingual/buccal (2) surfaces with extensions and anatomical contours for crowns of the upper and lower dental arches.

PHARMACEUTICAL PREPARATION AND METHOD OF ITS PRODUCTION AND USE
20170312221 · 2017-11-02 ·

Thus, the present invention provides a composition in powder form comprising highly dispersed silica particles, polymethylsiloxane particles, and a cationic surfactant, wherein at least 25% by weight of the cationic surfactant is present in primary polymethylsiloxane particles carrying the cationic surfactant on their surface and/or in agglomerates of these primary particles.

Antimicrobial And Biological Active Polymer Composites And Related Methods, Materials and Devices
20170304815 · 2017-10-26 ·

Biologically activated ion-exchange polymer salts are made by exchanging biologically active ionic agents onto ion-exchange polymers. The activated polymers are uniquely surface active and stable to thermal degradation and chemical and other forms of decomposition. The activated ion-exchange polymer salts may be processed and combined with polymer precursors using novel methods and materials to produce stable, biologically activated polymer composites, including antimicrobial and antifouling polymer composites.

Composition comprising hyaluronic acid and mepivacaine
09789226 · 2017-10-17 · ·

Compositions and methods for the surface appearance of the skin a subject are provided. An injectable composition comprising at least hyaluronic acid or a salt thereof; and an effective amount of at least mepivacaine or a salt thereof are provided. The hyaluronic acid optionally has an average molecular weight ranging from 50,000 to 10,000,000 Daltons, and may be crosslinked hyaluronic acids, non-crosslinked hyaluronic acids, or a combination, in some embodiments. The compositions and methods of the present invention are useful for treating and preventing the cutaneous signs of chronological aging and/or induced by external factors such as stress, air pollution, tobacco or prolonged exposure to ultraviolet (UV) exposure, impaired surface appearance of the skin, impaired viscoelastic or biomechanical properties of the skin, and/or the long-lasting filling of volume defects of the skin.